Cash position of €7.5 million as of December 31, 2024 BioChaperone Lispro final dosing of Phase 3 triggered a $10 million revenue recognition, and top-line data are expected in mid-2025 ...

Capital increase of a total amount of €9.7 million in gross proceeds by issuing a total number of 2,125,000 new shares, each with one share warrant attached, at €4.58 per share Gross Proceeds ...